Professional Marketing briefs

Share this article:
A convention graphic for Alcon's Travatan Z, an ophthalmic drop, broadened the product's indication and made unsubstantiated superiority claims, according to a DDMAC Untitled Letter. Although Travatan Z received a broadened indication from FDA in August—the eye drop is now indicated as a first-line therapy —that “was not the case at the time of [the ad's] initial dissemination,” according to the Untitled Letter.

Despite ongoing sales force reductions at many large pharmas, physicians still get around 20 visits from sales reps each week, according to an SK&A survey. Of the physicians surveyed, half said they prefer or require an appointment to see a rep (up from 38.5% in 2008), while 23% won't see reps at all, according to the survey data. Practices owned by hospitals or health systems are tougher to get into than private practices, since appointments have to go through headquarters, the survey found.

A meta-analysis published in PLoS Medicine found that professional promotion, including rep visits, journal ads and sponsored meetings, does nothing to improve the quality of prescribing, as measured by guideline adherence, safety and effectiveness.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters